drugset / Trial / NCT00094757

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

NCT00094757

Phase 3 Completed 521 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and effectiveness of an investigational drug in patients with Type 2 Diabetes Mellitus.

Timeline

Start
2004-10-06
Primary completion
2005-08-17
Completion
2006-04-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pioglitazone Small molecule 30 mg Oral
Subject Sitagliptin Small molecule 100 mg Oral
Subject Sitagliptin Small molecule 200 mg Oral